Hopman Mark: insider trades.
Hopman Mark reported 5 non-derivative transactions on 5 SEC ownership filings in Q3 2026: 0 open-market purchases and 5 sales ($2.1M), across 1 company.
- Transactions
- 5
- Purchases (P)
- 0
- Sales (S)
- 5
- Companies
- 1
- Name as filed
- Hopman Mark
Companies
| Company | Relationship | Transactions |
|---|---|---|
| Beta Bionics, Inc. (BBNX) | Officer · Chief Commercial Officer | 5 |
Transactions
| Date | Company | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-16 | Beta Bionics, Inc. | S | 30,779 | $20.13 | 56,479 | Form 4 |
| 2026-09-14 | Beta Bionics, Inc. | S | 775 | $15.52 | 86,382 | Form 4 |
| 2026-09-09 | Beta Bionics, Inc. | S | 35,994 | $18.46 | 88,033 | Form 4/A |
| 2026-09-09 | Beta Bionics, Inc. | S | 36,870 | $18.46 | 87,157 | Form 4 |
| 2026-09-02 | Beta Bionics, Inc. | S | 5,327 | $19.11 | 124,027 | Form 4 |
Questions
What stock did Hopman Mark buy or sell?
Hopman Mark reported 5 non-derivative transactions on 5 SEC ownership filings in Q3 2026: 0 open-market purchases and 5 sales ($2.1M), across 1 company.
Is Hopman Mark the same person as other filers with this name?
This page covers SEC CIK 2048497 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.
Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.
Plain-text version for agents and LLMs: /insiders/hopman-mark-2048497.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.